AReproducibl ePorcin eePTF EArteria lBypas sMode lfor Neointima lHyperplasia 1

Background. Late failure of prosthetic vascular bypass grafting using expanded polytetrafluoroethylene (ePTFE) is secondary to the development of neointimal hyperplasia, most commonly at the distal anastomosis. To develop therapies that can improve upon current prosthetic vascular bypass grafting, a large animal model of prosthetic bypass grafting that results in reproducible neointimal hyperplasia is necessary. Methods. We performed bilateral end-to-side carotid artery bypasses with 6 mm ePTFE in a porcine model (n 11). We studied graft patency using magnetic resonance angiography (MRA, 3 wk), duplex ultrasonography (4 wk), and digital-subtraction contrast angiography (4 wk). Animals were sacrificed at 4 wk and morphometric analysis was performed. Results. Of the 11 animals that underwent surgery, one pig died from respiratory compromise; of the remaining 10, graft patency was 90% at 4 wk. Peak systolic and end diastolic velocities were established for this model using ultrasonography. MRA, ultrasonography, and angiography confirmed graft patency and were complimentary tools to evaluate the grafts. Development of neointimal hyperplasia was reproducible at 4 wk in both the proximal and distal anastomoses (2.5 to 3 mm 2 ) of the ePTFE bypass grafts. Conclusion. We developed a reproducible porcine ePTFE carotid artery bypass model for studying neointimal hyperplasia. Not only does this model allow for the manipulation and evaluation of potential therapies, but patency and neointimal hyperplasia can be easily evaluated by traditional means, such as MRA, ultrasonography, and angiography. This preclinical model is ideal for evaluation of novel therapies in vivo designed to inhibit neointimal hyperplasia following arterial reconstruction with prosthetic bypass

[1]  T. Fabian,et al.  The Effect of Bacterial Contamination on Neointimal Hyperplasia in Vascular Grafts , 2006, The American surgeon.

[2]  Scott A Berceli,et al.  Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. , 2006, Journal of vascular surgery.

[3]  Prevent Iv Investigators Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. , 2005 .

[4]  T. Fabian,et al.  Rapamycin-coated expanded polytetrafluoroethylene bypass grafts exhibit decreased anastomotic neointimal hyperplasia in a porcine model. , 2005, Journal of vascular surgery.

[5]  E. Mattsson,et al.  Healing of PTFE grafts in a pig model recruit neointimal cells from different sources and do not endothelialize. , 2005, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[6]  H. Haruguchi,et al.  Intimal hyperplasia and hemodynamic factors in arterial bypass and arteriovenous grafts: a review , 2003, Journal of Artificial Organs.

[7]  J. Kastelein,et al.  Rapid, arteriovenous graft failure due to intimal hyperplasia: a porcine, bilateral, carotid arteriovenous graft model. , 2003, The Journal of surgical research.

[8]  R. Dreesen,et al.  The porcine hemodialysis access model. , 2001, Journal of vascular and interventional radiology : JVIR.

[9]  Simon C Watkins,et al.  Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia. , 2001, Journal of vascular surgery.

[10]  M. Mann,et al.  Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. , 2001, The Journal of thoracic and cardiovascular surgery.

[11]  J. Polak,et al.  Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial , 1999, The Lancet.

[12]  Robin J. Prescott,et al.  Randomized trial comparing infrainguinal polytetrafluoroethylene bypass grafting with and without vein interposition cuff at the distal anastomosis , 1997 .

[13]  T. Ogihara,et al.  A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Davies,et al.  Pathobiology of intimal hyperplasia , 1994, The British journal of surgery.

[15]  K. Bailey,et al.  Differential neointimal response to coronary artery injury in pigs and dogs. Implications for restenosis models. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[16]  V. Fuster,et al.  A dilemma for the 1990s. Choosing appropriate experimental animal model for the prevention of restenosis. , 1992, Circulation.

[17]  M. Reidy,et al.  Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[18]  G L'Italien,et al.  Effect of compliance mismatch on vascular graft patency. , 1987, Journal of vascular surgery.

[19]  V. Bernhard,et al.  Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. , 1986, Journal of vascular surgery.

[20]  M. Reidy,et al.  Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. , 1983, Laboratory investigation; a journal of technical methods and pathology.

[21]  M. Reidy,et al.  Mechanisms of stenosis after arterial injury. , 1983, Laboratory investigation; a journal of technical methods and pathology.

[22]  L. Sauvage,et al.  Healing of Arterial Prostheses in Man: Its Incompleteness , 1972, Annals of surgery.

[23]  R. Mason,et al.  Some species differences in fibrinolysis and blood coagulation. , 1971, Journal of biomedical materials research.